
Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies
Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies Azafaros, a clinical-stage biotechnology company with a specialized focus on rare lysosomal storage disorders (LSDs), announced the successful…











